Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder-A preliminary report

Journal of Affective Disorders

Volumn 92, Issue 2-3, 2006, Pages 277-281

  Dávila, Ricardo ^a   Zumárraga, Mercedes ^a   Basterreche, Nieves ^a   Arrúe, Aurora ^a   Zamalloa, M Isabel ^a   Anguiano, Juan B ^b  

^a Hospital Psiquiatrico de Zamudio   (Spain)

^b Centro de Salud Mental de Ortuella   (Spain)

Author keywords

3 Methoxy 4 hydroxyphenylglycol; Bipolar disorder; Catechol O methyltransferase; Homovanillic acid; Psychosis

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; DOPAMINE; HOMOVANILLIC ACID; LITHIUM; NORADRENALIN; OLANZAPINE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BLOOD LEVEL; CATECHOLAMINE BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOSIS; SAMPLE SIZE; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOGENIC MONOAMINES; BIPOLAR DISORDER; CATECHOL O-METHYLTRANSFERASE; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOVANILLIC ACID; HUMANS; LITHIUM CARBONATE; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33747743062     PISSN: 01650327     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jad.2006.02.009     Document Type: Article

References (28)

1. Akil M., Kolachana B.S., Rothmond D.A., Hyde T.M., Weinberger D.R., and Kleinman J.E. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J. Neurosci. 15 (2003) 2008-2013
2. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) (1984), University of Iowa, Iowa City
3. Bilder R.M., Volavka J., Lachman H.M., and Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 29 (2004) 1943-1961
4. Bowers Jr. M.B., Swigar M.E., Jatlow P.I., Hoffman F.J., and Goicoechea N. Early neuroleptic response: clinical profiles and plasma catecholamine metabolites. J. Clin. Psychopharmacol. 7 (1987) 83-86
5. Colom F., Vieta E., Martínez-Arán A., García-García A., Rainares M., Torrent C., Goikolea J.M., Banus S., and Salamero M. Versión española de la escala de evaluación de la manía: validez y fiabilidad de la escala de Young. Med. Clin. (Barc) 119 (2002) 366-371
6. Davidson M., and Davis K.L. A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls. Arch. Gen. Psychiatry 20 (1987) 307-312
7. Dávila R. Plasma HVA, neuroleptics, and dopaminergic plasticity. Biol. Psychiatry 25 (1989) 1-3
8. Dávila R., Manero E., Zumárraga M., Andía I., Schweitzer J.W., and Friedhoff A.J. Plasma homovanillic acid is a predictor of response to neuroleptics. Arch. Gen. Psychiatry 45 (1988) 564-567
9. Dávila R., González-Torres M.A., Zumárraga M., Andía I., Guimón J., Silva R.R., and Friedhoff A.J. Plasma prolactine and plasma homovanillic acid predictors of clinical response in schizophrenia. Biol. Psychiatry 38 (1995) 267-269
10. Dávila R., Zumárraga M., Andía I., Almoguera-Abad A., and Friedhoff A.J. Early increase of plasma HVA during neuroleptic treatment: a tool for outcome prediction and subtyping of schizophrenia. In: Friedhoff A.J., and Amin A. (Eds). Homovanillic Acid in Schizophrenia (1997), American Psychiatric Press, Washington, DC 89-102
11. Green A.I., Alam M.Y., Boshes R.A., Waternaux C., Pappalardo K.M., Fitzgibbon M.E., Tsuang M.T., and Schildkraut J.J. Haloperidol response and plasma catecholamines and their metabolites. Schizophr. Res. 10 (1993) 33-37
12. Gutierrez B., Bertranpetit J., Guillamat R., Valles V., Arranz M.J., Kerwin R., and Fañanas L. Association analysis of the catechol-O-methyltransferase gene and bipolar affective disorder. Am. J. Psychiatry 154 (1997) 113-115
13. Kunugi H., Vallada H.P., Hoda F., Kirov G., Gill M., Aitchison K.J., Ball D., Arranz M.J., Murray R.M., and Collier D.A. No evidence for an association of affective disorders with high- or low-activity allele of catechol-O-methyltransferase gene. Biol. Psychiatry 42 (1997) 282-285
14. Mazure C.M., and Bowers M.B. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis. J. Affect. Disord. 48 (1998) 83-86
15. Meltzer H.Y., Li Z., Kaneda Y., and Ichicawa J. Serotonin receptor: their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
16. Palmatier M.A., Kang A.M., and Kidd K.K. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol. Psychiatry 46 (1999) 557-567
17. Pickar D., Labarca R., Doran A.R., Wolkowitz O.M., Roy A., Breier A., Linnoila M., and Paul S.M. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients: correlation with psychosis and response to clinical treatment. Arch. Gen. Psychiatry 43 (1986) 669-676
18. Rizzo V., and Melxi Devil G.V. Determination of free MHPG in plasma and CSF by HPLC. Clin. Chem. 33 (1987) 844-845
19. Rotondo A., Mazzanti C., Dell'Osso L., Rucci P., Sullivan P., Bouanani S., Gonnelli C., Goldman D., and Cassano G.B. Catechol-O-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am. J. Psychiatry 159 (2002) 23-29
20. Seeman P., Weinshenker D., Quirion R., Srivastava L.K., Bhardwaj S.K., Grandy D.K., Premont R.T., Sotnikova T.F., Boksa P., El-Ghundi M., O'Dowd B.F., George S.R., Perreault M.L., Männisto P.T., Robinson S., Palmiter R.D., and Tallerico T. Dopamine supersensitivity correlates with D2 high states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3513-3518
21. Serretti A., Lorenzi C., Lilli R., Mandelli L., Pirovano A., and Smeraldi E. Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO A, and Gβ3 variants. Am. J. Med. Genet. (Neuropsychiatric Genetics) 114 (2002) 370-379
22. Spearing M.K., Post R.M., Leverich G.S., Brandt D., and Nolen W. Modification of the clinical global impression (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 73 (1997) 159-171
23. Sumiyoshi T., Roy A., Kim C.H., Jayathilake K., Lee M.A., Sumiyoshi C., and Meltzer H.Y. Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. Psychopharmacology 177 (2004) 79-83
24. Tsuang M.T., Stone W.S., Tarbox S.I., and Faraone S.V. An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophr. Res. 54 (2002) 169-175
25. Weinberger D.R., Egan M.F., Beertolino A., Callicot J.H., Mattay V.S., Lipska B.K., Berman K.F., and Goldberg T.E. Prefrontal neurons and the genetics of schizophrenia. Biol. Psychiatry 50 (2001) 825-844
26. Weinshilboum R.M., Otterness D.M., and Szumlanski C.L. Methylation pharmacogenetics: catechol-O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39 (1999) 19-52
27. Young L.T., Warsh J.J., Kish S.J., Shannak K., and Hornykeiwicz O. Reduced brain 5-HT and elevated NE turnover and metabolites in bipolar affective disorder. Biol. Psychiatry 35 (1994) 121-127
28. Zumárraga M., Andía I., Dávila R., and Zamalloa M.I. Homovanillic acid in plasma determined by HPLC with direct injection of plasma filtrates. Clin. Chem. 40 (1994) 2119-2120